Development of a New Patient-reported Outcome (PRO) Measure for Depression: Progress and Results from the PRO Consortium
Track
:
Track 07: Processes and Technologies for Clinical Research
Program Code:
209
Date:
Tuesday, June 25, 2013
Time:
8:00 AM to 9:30 AM
EST
Location:
251
CHAIR
:
Stephen Joel Coons, PhD,MEd,MSc (SCHNON), Executive Director, PRO Consortium, Critical Path Institute, United States
Stephen Joel Coons is Executive Director of the Patient-Reported Outcome (PRO) Consortium at the Critical Path Institute (C-Path). Stephen joined C-Path after a 23-year career in academia. For the past two decades, his primary research focus has been the measurement of patient-reported outcomes.
Elektra is dermatologist by training has been a medical officer at the FDA since 2001 and with SEALD since 2007. Elektra works in clinical outcome assessment review and qualification and has participated in the development of the FDA PRO guidance as well as the DDT qualification guidance.
Steven I. Blum, MA,MBA (SPKNON), Director, Health Economics, Forest Research Institute, United States
Steve Blum is a Director in the Health Economics/Outcomes Research group at Forest Research Institute, where he’s the HEOR Therapeutic Area Lead for CNS. He has worked at Forest and its corporate parent for 20 years. In 2011, he was selected as an Emerging Pharma Leader by Pharmaceutical Executive.
Mona L. Martin, MPA,RN (SPKNON), Executive Director, Research Scientist, Health Research Associates Inc., United States
After spending 9 years in the area of research methods and instrument development for health promotion programs, she became one of the founding partners, and Director of Health Research Associates (HRA).
Description
Gain an understanding of the research conducted by the PRO Consortium's Depression Working Group to develop a new patient-reported outcome (PRO) measure for depression which is intended for use as an endpoint to support medical product labeling.